Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
| Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
5.14 | 5.91 | 8.53 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(35.97) | (23.92) | (19.53) | (9.85) | (16.53) | (5.85) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(3.30) | (5.27) | 21.08 | (31.23) | (2.88) | (2.19) | — |
P/B ratio |
4.40 | 1.04 | 1.85 | 2.29 | 0.42 | 0.98 | — |
Price to Tangible BV |
4.41 | 1.04 | 1.86 | 2.30 | 0.42 | 0.98 | — |
EV/Sales |
(0.29) | (1.22) | 3.55 | 0.00 | 0.00 | 0.00 | — |
EV/EBITDA |
0.04 | 0.23 | 0.00 | 0.00 | 0.32 | 0.00 | — |
EV/Operating CF |
0.04 | 0.28 | (3.04) | (6.06) | 0.83 | (0.05) | — |
EV/FCF |
0.04 | 0.25 | (2.24) | (4.83) | 0.73 | (0.04) | — |
Quick Ratio |
2.43 | 3.31 | 6.40 | 13.11 | 29.42 | 14.51 | 3.69 |
Current Ratio |
2.62 | 3.50 | 6.52 | 13.73 | 29.96 | 14.61 | 3.77 |
Net Debt/EBITDA |
0.77 | 1.50 | 2.09 | 3.06 | 0.67 | 0.90 | 2.09 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 10.54% | 5.79% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.07 | 0.00 |
Asset Turnover |
0.14 | 0.11 | 0.08 | 0.06 | 0.02 | 0.27 | 0.00 |
Operating CF/Net income |
0.85 | 0.82 | 0.40 | 0.94 | 0.38 | 1.37 | 0.42 |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | (0.03) | (13.84) | (0.42) |
Interest Coverage |
(108.48) | (1,098.62) | (120.72) | (21.31) | (31.05) | (160.00) | (187.39) |
| (288.67%) | (86.74%) | (52.16%) | (28.25%) | (106.98%) | (72.69%) | (58.50%) | |
| (117.47%) | (57.79%) | (40.77%) | (24.04%) | (93.52%) | (56.78%) | (49.02%) | |
ROIC |
0.00% | 0.00% | 0.00% | (347.61%) | (458.62%) | (750.23%) | 0.00% |
Return on Tangible Assets |
(211.25%) | (86.61%) | (57.90%) | (28.00%) | (136.01%) | (110.49%) | (63.43%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
732.60% | 504.45% | 309.94% | 270.06% | 807.80% | 236.53% | 0.00% |
Selling, General and Administrative Expense of Revenue |
142.67% | 141.76% | 229.82% | 288.05% | 1,998.18% | 74.68% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
28.02% | 30.33% | 34.58% | 71.51% | 1,177.17% | 33.37% | 0.00% |
Graham Net Nets |
0.14 | 0.85 | 0.47 | 0.35 | 1.92 | 0.87 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(170.54%) | (88.58%) | (34.57%) | (11.56%) | (256.23%) | (105.20%) | — |
Free Cash Flow Yield |
(145.82%) | (83.07%) | (18.53%) | (13.52%) | (133.08%) | (148.84%) | — |
Revenue per Share |
0.25 | 0.37 | 0.36 | 0.41 | 0.19 | 6.81 | 0.00 |
Operating CF per Share |
(1.79) | (1.60) | (0.77) | (1.47) | (4.08) | (19.81) | (7.92) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.73) | (0.02) |
Free Cash Flow per Share |
(1.79) | (1.60) | (0.77) | (1.47) | (4.08) | (20.54) | (7.94) |
Cash per Share |
1.48 | 2.96 | 3.83 | 5.62 | 7.95 | 13.82 | 39.20 |
Shareholders Equity per Share |
0.29 | 2.10 | 3.04 | 5.96 | 8.36 | 14.10 | 29.44 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.29 | 2.10 | 3.04 | 5.96 | 8.36 | 14.10 | 29.44 |
Free Cash Flow |
(65.09) | (32.18) | (12.17) | (17.08) | (29.29) | (120.59) | (40.72) |
Working Capital |
35.86 | 44.80 | 52.23 | 63.25 | 56.09 | 76.12 | 150.80 |
Capital Expenditures |
(0.01) | — | — | — | (0.03) | (4.30) | (0.09) |
Net Current Asset Value |
6.47 | 37.18 | 42.03 | 55.14 | 48.51 | 70.69 | 150.80 |
EV/EBIT |
0.04 | 0.22 | 0.00 | 0.00 | 0.32 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.11 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||
Depreciation/Fixed assets |
3.28 | 2.44 | 3.48 | 0.28 | 33.13 | 0.39 | 0.81 |
Cash ROIC |
(101.16%) | (31.66%) | (11.21%) | (12.73%) | (23.57%) | (71.22%) | (11.56%) |
Accounts Receivable Turnover |
154.86 | 5.87 | 0.00 | 3.06 | 3.97 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | — | 0.00 |
Average Receivables |
0.06 | 1.27 | — | 1.56 | 0.35 | — | — |
Average Payables |
5.71 | 2.58 | 1.79 | 0.75 | 0.96 | 1.43 | 1.51 |
Average Assets |
64.97 | 67.75 | 74.92 | 75.80 | 81.62 | 149.67 | 195.45 |
Average Common Equity |
26.44 | 45.14 | 58.55 | 64.50 | 71.35 | 116.91 | 163.78 |
Columns are period end dates